American Society of Clinical Oncology,
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease…
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease…
Read Now: Fixed-Duration Venetoclax-Rituximab Improves Outcomes in R/R CLL- simultaneously published in JCO with presentation…